echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > A thorough investigation of hospital rebates violations will suspend trading in the consumables market.

    A thorough investigation of hospital rebates violations will suspend trading in the consumables market.

    • Last Update: 2020-10-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Medical Network September 16th, September 14th, the Central Commission for Discipline Inspection, the State Supervision Commission website micro-published "after being blacklisted as a briber..." article, the contents of the medical field, the State Health Insurance Administration is also studying the establishment of pharmaceutical prices and the list of matters of mis-trust, which, within the province at all levels of various medical institutions, centralized procurement agencies and their staff to carry out commercial bribery of medicine, a single case of bribery amount of more than 1 million yuan of pharmaceutical enterprises, the amount of credit will be assessed as "particularly serious."
    The Central Commission for Discipline Inspection pointed out that in recent times, many people due to bribery and other issues included in the project bidding outstanding issues of the first batch of serious mis-trust blacklist and notification, causing widespread concern.
    that blacklisted enterprises and individuals will face restrictions on bidding activities, disqualification from financial subsidies, strengthen tax monitoring and management, increase loan interest rates and a series of disciplinary measures.
    bribery not only destroys fair competition in the market and pollutes the industry atmosphere, but also seriously corrupts the cadre.
    clearly put forward, insist on taking bribes and bribery together to investigate.
    establishment of a blacklist of bribers will help to combat bribery and eradicate the breeding ground for corruption.
    end of April this year, Hunan Provincial Public Resources Trading Management Committee and the Provincial Commission for Discipline Inspection organized the construction project bidding outstanding issues of the special rectification officially started.
    public release of the project construction field of the main body blacklist, is one of the important links of this special rectification.
    Comb found that the blacklisted main body of the failure of trust, including enterprises and individuals, the most common act of disrelimony is to collude with each other to bid, in addition, by means of bribery to obtain the project, loan or hang on to qualifications, after winning the bid will be subcontracted projects, illegal subcontracts are not in the minority.
    the violation will suspend the market transactions of consumables to hospital doctors to give kickbacks, the persons involved will be included in the list of breach of trust.
    The State Health Insurance Administration recently issued the Guidance on the Establishment of a System for the Evaluation of Pharmaceutical Prices and The Recruitment of Credits (Draft for Comments), which states that the practice of receiving kickbacks and monopolizing the control of sales in the pharmaceutical field has caused the inflated prices of medicines and medical supplies to infringe on the interests of the masses.
    The National Health Insurance Administration will establish a system of evaluation of pharmaceutical prices and credit.
    so what does this system contain, and how exactly is it built? Pharmaceutical companies' credit ratings will be rated on four levels and updated quarterly.
    In accordance with the requirements of "reliable source, clear conditions, strict procedures, strict operation", the implementation of credit rating, according to the nature of the act of disrelition, circumstances, limitations, and the scope of influence and other factors, pharmaceutical enterprises in the local tender procurement market, the situation of the failure of trust is assessed as general, medium, serious, particularly serious four levels, dynamic updates on a quarterly basis.
    the facts on which the credit rating is based shall be based on the court decision or the administrative penalty decision of the law enforcement department for the breach of trust involving the violation of the law.
    to encourage local exploration of quantitative scoring credit rating methods, improve the level of standardization of credit ratings.
    Centralized purchasing agencies shall, in accordance with the credit rating of pharmaceutical enterprises, adopt written reminders and warnings, rely on centralized procurement platforms to alert purchaser to risk information, suspend the bidding and hanging of relevant drugs or medical supplies, and suspend the eligibility for the supply and distribution of winning drugs or medical supplies.
    , the public disclosure of breach of trust information and other disposal measures, the implementation of pharmaceutical enterprises breach of trust liability.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.